Rimegepant for the Acute Treatment of Migraine in Adults From China
作者全名："Yu, Shengyuan; Guo, Aihong; Zhang, Mingjie; Wang, Zhen; Liu, Jianguang; Tan, Ge; Yang, Qian; Liu, Yu; Zhao, Qian; Lu, Zhihong"
作者地址："[Yu, Shengyuan; Zhang, Mingjie] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China; [Guo, Aihong] Yanan Univ, Xianyang Hosp, Xianyang, Shaanxi, Peoples R China; [Wang, Zhen] Changsha Cent Hosp, Changsha, Hunan, Peoples R China; [Liu, Jianguang] Wuhan Third Hosp, Wuhan, Hubei, Peoples R China; [Tan, Ge] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China; [Yang, Qian] Shanxi Prov Hosp, Xian, Shanxi, Peoples R China; [Liu, Yu] Pfizer Inc, Beijing, Peoples R China; [Zhao, Qian] Pfizer Inc, Chengdu, Peoples R China; [Lu, Zhihong] Pfizer China Res & Dev Ltd, Shanghai, Peoples R China"
通信作者：
来源：CEPHALALGIA
ESI学科分类：NEUROSCIENCE & BEHAVIOR
WOS号：WOS:001125614000349
JCR分区：Q1
影响因子：5
年份：2023
卷号：43
期号：1supp
开始页：212
结束页：213
文献类型：Meeting Abstract
关键词：
摘要：
基金机构：Biohaven; Pfizer
基金资助正文："This study was sponsored by Biohaven which was acquired by Pfizer in October 2022. Zhihong Lu, Yu Liu, and Qian Zhao are employees of Pfizer. The remaining authors declare no conflicts of interest. Medical writing support was provided by Matt Soulsby, PhD, CMPP, of Engage Scientific Solutions and was funded by Pfizer."
